Log In
BCIQ
Print this Print this
 

HepaGam B (ImmunoGam)

Also known as: Anti-hepatitis B hyperimmune purified antibody

  Manage Alerts
Collapse Summary General Information
Company Aptevo Therapeutics Inc.
DescriptionAnti-hepatitis B hyperimmune globulin
Molecular Target HBV antigens
Mechanism of ActionBinds hepatitis B surface antigen (HBsAg)
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis B virus (HBV)
Indication DetailsPrevent hepatitis B recurrence following liver transplantation in hepatitis B surface antigen-positive liver transplant patients; Treat post-exposure hepatitis B infection
Regulatory Designation
PartnerTzamal Medical Group Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$222.0M

$222.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/06/2015

Undisclosed

Undisclosed

Undisclosed

02/21/2014

$222.0M

$222.0M

0

Get a free BioCentury trial today